endpts.com·May 18, 2026
Merck and Kelun-Biotech's experimental antibody-drug conjugate achieved success in a global Phase 3 study, marking a significant pipeline win for Merck as it nears the patent expiration of its top-selling product.
Merck's success with the experimental antibody-drug conjugate in a global Phase 3 study highlights a significant pipeline advancement, showcasing the potential of strategic partnerships in drug development. This is particularly relevant for those monitoring pharmaceutical innovations and collaborations as it suggests a viable approach to overcoming patent cliffs and sustaining product pipelines. Consider exploring partnership opportunities in similar biotech collaborations to bolster your healthtech and biotech strategies.